Angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) are commonly prescribed for hypertension, but their differential effects on insulin sensitivity and diabetes risk remain unclear. The gene discussed is INS; the disease is diabetes mellitus.